Anaptysbio Inc (ANAB) Stock Price, Quote & News

Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared co...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 362 6295

Website: www.anaptysbio.com

Address:

10770 Wateridge Circle, Suite 210, San Diego, United States

IN0V8 Feb. 20 at 8:56 PM

$ANAB Opportunity Barclays raises target price to $78 from $55

0 · Reply

OfficialStocktwitsUser Feb. 19 at 9:27 PM

$ANAB RSI: 69.56, MACD: 2.1256 Vol: 3.00, MA20: 50.48, MA50: 48.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StockBraker Feb. 17 at 10:38 PM

$ANAB https://finance.yahoo.com/news/anaptysbio-details-q2-royalty-spin-200852887.html

1 · Reply

StockBraker Feb. 12 at 2:22 PM

$ANAB Looking for $65 now.

0 · Reply

Justlooking121212 Feb. 11 at 9:05 PM

$ANAB What is happening?

0 · Reply

StockBraker Feb. 11 at 8:07 PM

$ANAB https://ir.anaptysbio.com/static-files/d12275b2-d99f-4a2e-8697-de3a6969ec68

1 · Reply

Neeter Feb. 11 at 8:05 PM

$ANAB Nice breakout at 52.47

0 · Reply

StockBraker Feb. 11 at 7:50 PM

$ANAB Big announcement coming at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026??

0 · Reply

StockConsultant Feb. 11 at 7:47 PM

$ANAB AnaptysBio stock, nice top of range breakout, from Stocks to Watch at https://stockconsultant.com/?ANAB

0 · Reply

StockBraker Feb. 11 at 7:15 PM

$ANAB Okay - So I was early again. Sue me.

0 · Reply

Anaptys Announces Participation at Upcoming Investor Conferences

Jan 13, 2026, 11:25 PM EST - 5 weeks ago

AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 7:09 PM EST - 6 weeks ago

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

GSK

Jan 8, 2026, 6:00 PM EST - 6 weeks ago

Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Jan 6, 2026, 4:15 PM EST - 6 weeks ago

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 7:00 AM EST - 2 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA

Nov 25, 2025, 4:15 PM EST - 3 months ago

Anaptys Announces Participation in December Investor Conferences

Nov 21, 2025, 8:52 AM EST - 3 months ago

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

GSK

Nov 21, 2025, 8:48 AM EST - 3 months ago

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK

Nov 21, 2025, 6:14 AM EST - 3 months ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

GSK

Nov 21, 2025, 4:00 AM EST - 3 months ago

Anaptys Announces $100 Million Stock Repurchase Plan

Nov 21, 2025, 3:50 AM EST - 3 months ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

GSK

Nov 13, 2025, 7:30 AM EST - 3 months ago

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

Nov 10, 2025, 12:30 PM EST - 3 months ago

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

Nov 10, 2025, 9:00 AM EST - 3 months ago

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Nov 4, 2025, 4:15 PM EST - 3 months ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:15 PM EST - 3 months ago

Anaptys Announces Participation in November Investor Conferences

Oct 29, 2025, 9:15 AM EDT - 4 months ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Oct 15, 2025, 5:37 AM EDT - 4 months ago

AnaptysBio, Inc. - Special Call

Oct 13, 2025, 9:15 AM EDT - 4 months ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

Sep 30, 2025, 1:59 PM EDT - 5 months ago

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

Sep 29, 2025, 4:05 PM EDT - 5 months ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Sep 29, 2025, 4:05 PM EDT - 5 months ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Aug 27, 2025, 4:15 PM EDT - 6 months ago

Anaptys Announces Participation in September Investor Conferences

Aug 6, 2025, 4:15 PM EDT - 7 months ago

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 10, 2025, 1:33 PM EDT - 9 months ago

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Jun 6, 2025, 3:39 PM EDT - 9 months ago

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

Jun 4, 2025, 2:23 PM EDT - 9 months ago

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Jun 3, 2025, 4:05 PM EDT - 9 months ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

May 27, 2025, 4:15 PM EDT - 9 months ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 5, 2025, 4:15 PM EDT - 10 months ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Mar 24, 2025, 9:15 AM EDT - 11 months ago

Anaptys Announces Stock Repurchase Plan

Feb 27, 2025, 4:15 PM EST - 1 year ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in March Investor Conferences

Feb 12, 2025, 7:30 AM EST - 1 year ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 11, 2025, 5:30 PM EST - 1 year ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 3, 2025, 4:15 PM EST - 1 year ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 7:30 AM EST - 1 year ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Jan 7, 2025, 9:15 AM EST - 1 year ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 2:07 PM EST - 1 year ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Dec 11, 2024, 10:20 AM EST - 1 year ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 1 year ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:30 AM EST - 1 year ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 2:14 PM EDT - 1 year ago

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 14, 2024, 5:00 AM EDT - 1 year ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Aug 5, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 2:53 PM EDT - 1 year ago

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

May 9, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

IN0V8 Feb. 20 at 8:56 PM

$ANAB Opportunity Barclays raises target price to $78 from $55

0 · Reply

OfficialStocktwitsUser Feb. 19 at 9:27 PM

0 · Reply

StockBraker Feb. 17 at 10:38 PM

$ANAB https://finance.yahoo.com/news/anaptysbio-details-q2-royalty-spin-200852887.html

1 · Reply

StockBraker Feb. 12 at 2:22 PM

$ANAB Looking for $65 now.

0 · Reply

Justlooking121212 Feb. 11 at 9:05 PM

$ANAB What is happening?

0 · Reply

StockBraker Feb. 11 at 8:07 PM

$ANAB https://ir.anaptysbio.com/static-files/d12275b2-d99f-4a2e-8697-de3a6969ec68

1 · Reply

Neeter Feb. 11 at 8:05 PM

$ANAB Nice breakout at 52.47

0 · Reply

StockBraker Feb. 11 at 7:50 PM

$ANAB Big announcement coming at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026??

0 · Reply

StockConsultant Feb. 11 at 7:47 PM

$ANAB AnaptysBio stock, nice top of range breakout, from Stocks to Watch at https://stockconsultant.com/?ANAB

0 · Reply

StockBraker Feb. 11 at 7:15 PM

$ANAB Okay - So I was early again. Sue me.

0 · Reply

StockBraker Feb. 6 at 2:48 PM

$ANAB C’mon baby. Don’t make me regret my prediction. 😉

0 · Reply

BruceRobison704 Feb. 4 at 3:49 PM

$SMCL $ANAB Smaller healthcare names

0 · Reply

Topology Feb. 4 at 2:03 PM

$ANAB is a clinical-stage biotech developing antibody therapies for cancer and autoimmune diseases; its pipeline is promising but remains in early-stage development.

0 · Reply

StockConsultant Feb. 4 at 1:50 PM

$ANAB AnaptysBio stock, watch for a top of range breakout at https://stockconsultant.com/?ANAB

0 · Reply

OfficialStocktwitsUser Feb. 4 at 12:55 AM

$ANAB RSI: 58.33, MACD: 1.0927 Vol: 2.11, MA20: 47.30, MA50: 45.95 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StockBraker Feb. 3 at 1:46 AM

$ANAB I predict we will set a new 52 week high this week. Maybe in the $53-55 range.

1 · Reply

SuperGreenToday Jan. 23 at 10:27 PM

$ANAB Share Price: $47.47 Contract Selected: Aug 21, 2026 $45 Calls Buy Zone: $7.22 – $8.93 Target Zone: $12.88 – $15.74 Potential Upside: 68% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

StockBraker Jan. 20 at 2:18 PM

$ANAB Looking at the 6 month chart - The trend is your friend.

0 · Reply

StockBraker Jan. 14 at 9:56 PM

$ANAB AnaptysBio vs. Tesaro/GSK royalty dispute

1 · Reply

StockBraker Jan. 14 at 9:53 PM

$ANAB Welcome back to the $50's. Let's start working towards a new 52 week high.

0 · Reply

Reanimated666 Jan. 14 at 8:35 PM

$ANAB Morning dip beauty

0 · Reply

Reanimated666 Jan. 14 at 2:46 PM

$ANAB Long and Strong

0 · Reply

Market Cap	1.54B
Revenue (ttm)	91.28M
Net Income (ttm)	-145.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-159.10%
Debt to Equity Ratio	0.00

Volume	440,300
Avg Vol	472,970
Day's Range	N/A - N/A
Shares Out	27.69M
Stochastic %K	68%
Beta	0.35
Analysts	Strong Sell
Price Target	$67.92